Patritumab deruxtecan + Paclitaxel + Nab-paclitaxel + Capecitabine + Liposomal doxorubicin + Trastuzumab deruxtecan
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Neoplasms
Conditions
Breast Neoplasms
Trial Timeline
Jul 21, 2025 → Jul 14, 2033
NCT ID
NCT07060807About Patritumab deruxtecan + Paclitaxel + Nab-paclitaxel + Capecitabine + Liposomal doxorubicin + Trastuzumab deruxtecan
Patritumab deruxtecan + Paclitaxel + Nab-paclitaxel + Capecitabine + Liposomal doxorubicin + Trastuzumab deruxtecan is a phase 3 stage product being developed by Daiichi Sankyo for Breast Neoplasms. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07060807. Target conditions include Breast Neoplasms.
What happened to similar drugs?
20 of 20 similar drugs in Breast Neoplasms were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07060807 | Phase 3 | Recruiting |
Competing Products
20 competing products in Breast Neoplasms